American Journal of Clinical Pathology · 2004 · 69 citations · 0 references
MedicineMolecular BiologyOncologyMolecular OncologyOncogenesTumor PathologyBreast CytologyBreast PathologyCancer BiomarkersCancer Molecular DiagnosticsHer2-positive Breast CancerImmunohistochemistryBreast Fine Needle AspirationBreast Fine-needle Aspiration CytologyFna CytologyHer2 AmplificationHer2 Gene AmplificationImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical Staining
We evaluated HER-2 receptor status by immunocytochemical and immunohistochemical analyses and fluorescence in situ hybridization (FISH) in 51 fine-needle aspiration (FNA) specimens together with the corresponding formalin-fixed, paraffin-embedded (FFPE) tissue samples obtained from surgically resected breast cancers. Three fixation methods were compared: ethanol, formalin, and CytoLyt-ThinPrep (Cytyc, Boxborough, MA). HER-2 was overexpressed and amplified in 8 (16%) of 51 FFPE specimens. Of the 8 cases, gene amplification was observed in 8 FNA specimens (100%) and overexpression in 2 (25%) ethanol-, 4 (50%) CytoLyt-, and 5 (63%) formalin-fixed FNA specimens. Strong pairwise κ association between FISH results performed on FNA specimens and FFPE tissue samples (ethanol fixation, κ = 0.848; ThinPrep, κ = 0.918) and moderate (ThinPrep, κ = 0.692; formalin fixation, κ = 0.667) to poor (ethanol, κ = 0.300) pairwise κ agreement between tissue immunohistochemical and FNA immunocytochemical results was demonstrated. We conclude that HER-2 protein expression on cytologic preparations was insufficiently reliable for clinical use, whereas HER-2 gene amplification determined by FISH demonstrated strong and consistent correlation with HER-2 status of FFPE tissue samples.